Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Optimising the impact and cost-effectiveness of child health intervention programmes of vaccines and micronutrients in low-income countries (OPTIMUNISE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Denmark,Burkina Faso,Ghana,Germany,United Kingdom,Netherlands,Guinea-Bissau
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-03-01
End date: 2016-08-31
Duration (months): 66.0
Total project cost (EUR): 3978640.0
EU funding (EUR): 2999970.0
Participants: 8
Project status: CLOSED

International child health programmes in low-income countries are justified in term of their impact on child survival. However, the effect estimates are usually calculated from performance indicators and assumptions about efficacy based on small-scale target-specific studies. There is little follow-up of how the programmes are implemented in real life. This approach is clearly not sufficient. Recent studies have consistently shown that vaccines and micronutrients have non-specific effects, i.e. effects which are not explained by prevention of the targeted infections or deficiencies. These effects are often sex-differential. Furthermore, interventions may interact. Hence, the overall impact of child health programs can not be extrapolated from small-scale target-specific studies. There is a need to assess the real life impact and cost-effectiveness of child health intervention programmes in the context where they are being used. We propose to use health and demographic surveillance system (HDSS) sites in Africa to register information routinely on all interventions in childhood, such as all vaccinations, micronutrient supplementation, and de-worming, given at health centres or in campaigns. Using this information we will measure the overall health impact of the child health programs. The HDSS platform can also be used for testing modifications of the current health programmes. We will test a recent finding from a randomised trial in Guinea-Bissau: providing early measles vaccine at 4.5 and 9 months of age compared with the recommended measles vaccine at age 9 months reduced overall mortality from 4.5 to 36 months of age by astonishing 49%. The HDSS sites already collect data on mortality, and mortality would be the main outcome, but we also aim to identify other relevant comparable outcome parameters which correlate with mortality and which can be used to assess the overall impact of existing and new interventions.

Keywords: vaccines,vitamin a,child survival,health and demographic surveillance systems
Advanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency (CELL-PID)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Italy,France,United Kingdom,Germany,Israel,Germany,Netherlands,Germany,Germany,Switzerland,Germany,France,Germany,Türkiye,Belgium
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-11-01
End date: 2016-04-30
Duration (months): 66.0
Total project cost (EUR): 15799071.0
EU funding (EUR): 11887735.0
Participants: 20
Project status: CLOSED

Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity and high risk of cancer. Treatment entails hematopoietic stem cell (HSC) transplantation from allogeneic donors, however in the absence of an HLA compatible donor, HSCT outcome is limited by delayed or suboptimal reconstitution and complications. SCID-X1 and ADA-SCID have been successfully treated with autologous gene corrected HSC, however, associated with safety issues inherent to first generation retroviral vectors. This project utilizes genetically modified HSC and their descendants as immunotherapeutic cells to build a healthy immune system in PID patients, and is carried out by clinical centres, scientists and industrial partners pioneering in the field of advanced therapies and aiming at broad clinical application of safe cell-based therapeutic products. Multicentre phase I/II clinical trials for SCID-X1 and WAS are ready to start. Disease targeted technology to cure ADA-SCID, V(D)J recombination defects and CGD by gene corrected HSC and novel approaches in IPEX and HLH to gene modify already committed cells will be investigated. Based on rigorous preclinical efficacy and toxicology evaluation, flanked by basic studies aimed at improving HSC homing capacity and thymic epithelium regeneration, new clinical trials will be implemented. The consortium will establish a technology platform to implement, harmonize and run controlled, standardized multicentre preclinical studies using state-of-the-art advanced therapy. Strict observance of good practice quality guidelines and regulation of medicinal product development will be ensured. The successful completion of the project will be instrumental to accomplish and broaden clinical application of medicinal products able to rebuild and modulate the immune system with an anticipated impact that extends beyond PID to acquired immune disorders, allogeneic HSCT and cancer treatment.

Keywords: immune deficiency,thymic reconstitution,hematopoietic stem cell,cell therapy,gene transfer,viral vector,clinical trial.
DEVELOPING AND TESTING OF NEW METHODOLOGIES TO MONITOR AND EVALUATE HEALTH RELATED EU-FUNDED INTERVENTIONS IN COOPERATION PARTNER COUNTRIES (EVAL-HEALTH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Ethiopia,United Kingdom,Netherlands,Thailand,Nigeria,Spain,Portugal,India,Colombia
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-01-01
End date: 2014-10-31
Duration (months): 46.0
Total project cost (EUR): 3479337.6
EU funding (EUR): 2859568.6
Participants: 9
Project status: CLOSED

EVAL-HEALTH is an R&D project which has as its main goal to contribute to strengthen monitoring and evaluation of European Union (EU) funded interventions in developing countries in the specific area of Health, The major objectives of EVAL-HEALTH are: 1) To develop a sound methodological approach to evaluate and monitor implementation and performance of EU funded interventions in developing countries in the health sector by: i) Identifying best practices in M&E aid and their impact on health issues from major international donors and agencies active in the field. ii) obtaining comprehensive insight of the EC funded bilateral interventions in health sector. iii) Developing specific methodological models and tools for M&E of the impact of EU funded bilateral interventions (sector/budget support, Individual projects, R&D actions) iv) Testing on the field the suitability and applicability of the developed methodologies through case studies methodology. 2) To understand how the developed tools and methodologies adapts to different EU interventions. 3) To disseminate the results obtained in the project to the main project stakeholders as a means to increase and improve European funded interventions effectiveness in the health sector. EVAL-HEALTH is planned as a 46 month R&D project, with 9 participants from Spain, UK, the Netherlands Portugal, South Africa, Nigeria, Thailand, India and Colombia.The consortium will benefit from the inclusion of three high-level external Advisory Committees (Donors, Recipients and Scientific). These committees will be formed by relevant experts on M&E health aid in developing countries and will provide an important accumulated expertise to the project. As results of the EVAL-HEALTH project, EC Services and development partner countries will have improved methodologies specifically developed for health aid to strengthen M&E of EU funded interventions.

Keywords: monitoring,evaluation,m&e,indicators,health,eu funded interventions,methodologies,developing countries,health policy,aid effectiveness
Biobank Standardisation and Harmonisation for Research Excellence in the European Union (BIOSHARE-EU)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,Norway,Finland,Germany,Sweden,France,United Kingdom,Netherlands,Canada,Austria,United Kingdom,United Kingdom
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-12-01
End date: 2015-11-30
Duration (months): 60.0
Total project cost (EUR): 15653216.47
EU funding (EUR): 11998152.0
Participants: 17
Project status: CLOSED

Given contemporary understanding of the complexity of the causal architecture of common chronic diseases, the next stage of bioclinical scientific progress will depend critically on large-scale pooled analyses of high quality data from many biobanks and bioclinical studies. Such analyses will only be possible if we are able to harmonise and standardise the collection, storage, and management of data and bio-samples across biobanking studies. Recent consortium-based meta-analyses of genome-wide association studies (GWAS) have clearly demonstrated that it is possible to pool and analyse genomic data with broad indicators of disease status. But if health care science is to move quickly towards the exciting goals that have been envisaged for public health, clinical science, and personalised medicine a far greater challenge must now be overcome. That is, the standardization and harmonization of data and key measures of life-style, social circumstances and environment, as well as critical sub-components of the phenotypes associated with common complex diseases. This is the mission of BioSHaRE-EU. BioSHaRE-EU will work hand-in-hand with BBMRI (Biobanking and Bio-molecular Resources Research Infrastructure) and P3G (Public Population Project in Genomics), to build directly on extensive precursor work in the field of harmonisation and standardisation. The project will deliver tools to harmonize phenotypes of complex diseases, as well as lifestyle and environmental factors. In addition, it provides statistical methods and biostatistical tools for meta-analysis of large scale studies. These tools and methods will be developed and implemented in five large partner-biobanks: HUNT, KORA, LifeGene, LifeLines, UK-biobank. BioSHaRE-EU will also implement these in additional disease consortia of clinical biobanks, and other population-based biobanks.

Keywords: biobank,bbmri,harmonization,standardization
Assessing the impact of fee exemption on maternal health in West Africa and Morocco: new tools, new knowledge (FEMHEALTH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Belgium,United Kingdom,Morocco,Burkina Faso,Benin,Mali
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-01-01
End date: 2014-03-31
Duration (months): 39.0
Total project cost (EUR): 3716047.47
EU funding (EUR): 2883143.2
Participants: 9
Project status: CLOSED

There is a growing consensus that maternal health outcomes can only be improved through policies and programmes that combine interventions to address the different causes of ill health and target multiple groups. Such policies and programmes are complex in nature as they involve coordination between different tiers in the health system and multiple actors including communities, health workers and managers. User fee exemption for delivery and emergency obstetric care (EmOC) is one such policy that has been introduced by several African countries with the aim of improving access to care and thus improving maternal and neonatal outcomes. However, the current evidence base regarding the impact of this policy is not well developed, in part because of evaluation designs that are not able to capture all the necessary information for policy-makers to make informed decisions. This proposal aims to reduce this gap by developing research methodologies and tools that will lead to enhanced research on policy implementation, stronger evidence and improved dissemination.

Keywords: maternal health programmes cost effectiveness
International forum for European life sciences funders and performers (EUROBIOFORUM II)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Germany,France,Netherlands,Netherlands
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2011-01-01
End date: 2014-12-31
Duration (months): 48.0
Total project cost (EUR): 1411140.4
EU funding (EUR): 1217700.0
Participants: 4
Project status: CLOSED

In order to realize the full ERA potential new strategies are needed to help match research dynamics and funding opportunities, and meet societal challenges, in particular in health-related research. The EuroBioForum II project aims to create such a mechanism to foster the dialogue, cooperation and coordination between life sciences research funders and research performers. Annual conferences convening national agencies, intergovernmental organizations, private foundations, charities and industry will be organized to facilitate the exchange of information on respective ideas, initiatives and priorities and to discuss policy issues and scientific developments. Most importantly, research ideas providing the European scale and scope, necessitating a critical mass and a trans-national approach, will be presented by scientists and discussed in the form of brokerage events, initiating strategic discussions, within a network of European life sciences research funders and performers, on structure and finance of these projects. The conferences will provide a framework to foster the dialogue between the various bodies funding the life sciences, help achieve better programme and policy coordination and enhance synergies. Eurobiofund (FP6, 2006-2008) was the "first generation" example of this concept for an international forum. A survey carried out at the end of 2008 clearly indicated that Eurobiofund was a good concept that deserves to be continued in FP7. This international forum would to foster the ERA in life sciences research and be a step towards the identification and establishment of large scale research efforts in Europe that may suited for ERA-NET, ERA-NET+ or joint programming. Hence, EuroBioForum II will help formulate answers to some of the numerous challenges faced by the life sciences in Europe and make an essential contribution towards the realization of a single European market for research and address the unmet needs of society.

Keywords: life sciences health-related research research funding organisations international forum
EUCOMM: Tools for Functional Annotation of the Mouse Genome (EUCOMMTOOLS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Germany,Germany,Italy,France,Spain,United Kingdom,Spain,Australia,United States
Call:  (FP7-HEALTH-2010-single-stage, 2010)
Start date: 2010-10-01
End date: 2015-09-30
Duration (months): 60.0
Total project cost (EUR): 18169877.15
EU funding (EUR): 11999673.0
Participants: 11
Project status: CLOSED

The EUCOMMTOOLS Collaborative Project responds to the topic ‘HEALTH.2010.2.1.1-1: Large-scale efforts in mouse functional genomics to determine the functions of genes and their involvement in disease.’ EUCOMMTOOLS will provide, in a systematic high-throughput way, genetic tools and resources contributing to the determination of every gene’s function in any cell type of the entire organism at any given point in time. To contribute to the IKMC goals, EUCOMMTOOLS will establish 250 BAC-CreERT2 transgenic mice allowing inducible conditional gene inactivation in most cell types of the organism at any given point in time. Furthermore, EUCOMMTOOLS will establish 3.500 additional, conditionally targeted mouse ES cells to complete the IKMC resource. In addition, various important technological developments will valorise the EUCOMMTOOLS resources: a genetic toolkit for multipurpose usage of the conditional knockout alleles, and improvements of the Cre-recombinase function. The EUCOMMTOOLS Cre transgenic resource as well as its library of conditionally mutated mouse ES cells enables the establishment of mutant mice world-wide in a standardized, cost-effective and time-saving manner, making mouse mutants more easily available to the wider biomedical research community than possible previously. All EUCOMMTOOLS vectors, mutant ES cells and mice will be displayed via the EUCOMMTOOLS web portal and will be distributed by EuMMCR and EMMA to the scientific community. In general, EUCOMMTOOLS fosters existing European consortia which address mouse functional genomics, mouse mutant phenotyping, and mouse archiving. Taken together, EUCOMMTOOLS will further advance the functional annotation of the entire mouse genome and thereby enhance the understanding of the molecular basis of disease. Furthermore, it will support drug development by SMEs and the pharmaceutical industry.

Keywords: conditional mutagenesis,site-specific recombinases,animal models,disease models
European Exascale Software Initiative - 2010/2011 (EESI)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to policy development and Programme implementation
Action type: Coordination and support actions
Countries involved: France,Germany,Spain,Italy,United Kingdom,Netherlands
Call:  (FP7-INFRASTRUCTURES-2010-2, 2010)
Start date: 2010-06-01
End date: 2011-11-30
Duration (months): 18.0
Total project cost (EUR): 650010.0
EU funding (EUR): 640000.0
Participants: 8
Project status: CLOSED

The European Exascale Software Initiative (EESI) goal is to build a European vision and roadmap to address the challenge of the new generation of massively parallel systems composed of millions of heterogeneous cores which will provide Petaflop performances in 2010 and Exaflop performances in 2020. These capabilities lead to outstanding technological breakthrough possibilities in computations and simulations which will be reached only if an international cooperation work program is set up. This will be done through a set of conferences and work groups involving a very large number of HPC European actors and users. They will investigate where Europe stands in the overall international HPC landscape and competition, what are its strengths and weaknesses, and whether such or such topics and challenges should be addressed inside or outside Europe. EESI will also identify the sources of competitiveness for Europe induced by the development of Peta/Exascale solutions and usages. The overall challenge must be faced at worldwide level to be attainable. A close collaboration with the EU PRACE project which is preparing the tier-0 level of the European HPC ecosystem, will be implemented. Coordination with the International Exascale Software Project (IESP) launched by The Department Of Energy (Office of Science), National Science Foundation and Department Of Defense is planned. The project leader of IESP, Jack Dongarra, and the Japanese executive member of IESP, Satoshi Matsuoka, are contributing participants of EESI. Expected outputs of the project are a roadmap and a set of recommendations shared by the European HPC community, on tools, methods and applications to be developed for this new generation of supercomputers. Coordination with international actors working on the same goal will have been effectively established.

Keywords: high performance computing petascale exascale
NEXPReS- Novel EXplorations Pushing Robust e-VLBI Services (NEXPRES)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to existing research infrastructures
Action type: Combination of CP & CSA
Countries involved: Netherlands,Italy,Germany,United Kingdom,Sweden,Latvia,Spain,Denmark,Netherlands,Poland,United Kingdom,Finland,Australia
Call:  (FP7-INFRASTRUCTURES-2010-2, 2010)
Start date: 2010-07-01
End date: 2013-06-30
Duration (months): 36.0
Total project cost (EUR): 5792573.0
EU funding (EUR): 3500000.0
Participants: 15
Project status: CLOSED

The objective of “Novel EXplorations Pushing Robust e-VLBI Services” (NEXPReS) is to offer enhanced scientific performance for all use of the European VLBI Network (EVN) and its partners. The proposed activities will allow the introduction of an e-VLBI component to every experiment, aiming for enhanced robustness, flexibility and sensitivity. This will boost the scientific capability of this distributed facility and offer better data quality and deeper images of the radio sky to a larger number of astronomers. In the past years, e-VLBI has been successfully introduced for real-time, high-resolution radio astronomy. Due to limitations in connectivity, bandwidth and processing capacity, this enhanced mode cannot be offered to all astronomers yet, in spite of its obvious advantages. By providing transparent buffering mechanisms at telescope and correlator it will be possible to address all the current and future bottlenecks in e-VLBI, overcoming limited connectivity to essential stations or network failures, all but eliminating the need for physical transport of magnetic media. Such a scheme will be far more efficient, and ultimately greener, than the current model, in which complex logistics and a large over-capacity of disks are needed to accommodate global observations. It will require high-speed recording hardware, as well as software systems that hide all complexity. Real-time grid computing and high bandwidth on demand will be addressed as well, to improve both the continuous usage of the network and prepare the EVN for the higher bandwidths which will ensure it will remain the most sensitive VLBI array in the world. The proposed programme will strengthen the collaboration between the European radio-astronomical and ICT communities. This will be essential to maintain Europe's leading role in the global SKA project.

Keywords: radio astronomy,vlbi,radio telescopes,bandwidth on demand,streaming computing,high-speed storage,distributed sensor networks